Actively Recruiting
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-23
30
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
CONDITIONS
Official Title
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years old with ECOG performance status 0 or 1
- Unresectable or metastatic bladder cancer
- HER2 positive or suspicious positive tumors
- Previously treated with trastuzumab and taxane in advanced setting or progressed within 6 months after neoadjuvant or adjuvant trastuzumab and taxane treatment
- Adequate cardiac, bone marrow, kidney, liver, and blood clotting function
- Currently receiving anti-HER2 ADC treatment
- Life expectancy greater than 3 months
You will not qualify if you...
- Significant liver or kidney dysfunction
- Pregnant or planning to become pregnant
- Unable to remain still for half an hour
- Refusal to participate in the clinical research
- Claustrophobia or other mental disorders
- Any other condition deemed unsuitable by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
uEXPLORER total-body PET/CT scanner (United Imaging, China)
Beijing, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here